What happened with GEHC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Hospitals, health systems and researchers buy GE HealthCare’s equipment to diagnose conditions, guide procedures and monitor patients. Imaging is its largest business; together with ultrasound and procedure-guidance systems, it accounts for most revenue. The company also supplies patient-monitoring and life-support equipment. Product sales bring in more revenue than services, and no single customer dominates sales.
Equipment purchases lead to further business through long-term maintenance contracts, upgrades, replacement consumables and software subscriptions. GE HealthCare also services other manufacturers’ equipment, while its digital tools combine data from different vendors’ devices. A separate pharmaceutical diagnostics business sells contrast media and radioactive imaging agents used in scans, including scans performed on other suppliers’ equipment.
Equipment demand depends on healthcare providers’ purchasing budgets, while reimbursement from governments and health insurers affects what providers buy and use. Deliveries depend on a global supply network that includes some suppliers without identified alternatives; imaging agents require timely, reliable supply to avoid cancelled exams. Medical devices and pharmaceuticals must meet regulatory requirements for market access, manufacturing and continued sale.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
GE HealthCare’s results hinge on hospital imaging investment and diagnostic procedure volumes; Siemens Healthineers is an important global rival missing from this list.
Philips competes with GE HealthCare for hospitals’ and imaging providers’ spending on imaging systems, clinical software and services. Watch its Diagnosis & Treatment business, where combining imaging with software is central to its push to improve clinical workflow and productivity.
Lantheus Holdings, Inc sells diagnostic imaging agents to hospitals and imaging centers in competition with GE HealthCare, but also receives milestone payments and sales royalties for licensing flurpiridaz and Japanese piflufolastat rights to GE HealthCare. Its flurpiridaz royalties offer a read on GE HealthCare’s Flyrcado sales, with separate royalty terms for U.S. and non-U.S. sales.
Baxter competes with GE HealthCare for hospital purchases of patient-monitoring and diagnostic cardiology equipment. Its monitoring and heart-testing technologies are the relevant overlap, rather than its broad range of other hospital products.
GE HealthCare pays Plexus to develop and manufacture products, making Plexus a supplier rather than a rival selling its own equipment. GE HealthCare accounted for 10.3% of Plexus sales in fiscal 2023 and remained a customer in fiscal 2025, so sales attributable to GE HealthCare are the line to watch.
Butterfly Network, Inc. competes with GE HealthCare’s VScan for customers buying portable ultrasound for use at the point of care. Its handheld devices use a single semiconductor-based probe for whole-body imaging, making that product offering the comparison to watch against VScan.
iRhythm Holdings, Inc. competes with GE HealthCare’s traditional portable ECG recorders, known as Holter monitors, by selling physician-ordered cardiac-monitoring services using wearable patches. Watch its long-term monitoring services, which combine up to 14 days of ECG recording with analysis and reports sent to the prescribing physician.
Boston Scientific competes with GE HealthCare in cardiac monitoring through its Preventice business, which provides remote monitoring devices and services. Preventice is the relevant business to watch for this tie, rather than Boston Scientific’s broader portfolio of devices used in medical procedures.
iRadimed Corporation competes directly with GE HealthCare for hospital purchases of monitors that track vital signs inside MRI scanner rooms. Watch adoption of its 3880 monitor: iRadimed says customers may be reluctant to switch from established systems because its monitor is newer to the market.
GE HealthCare Technologies Inc. earningsThis company
GE HealthCare’s report will show whether growth in Imaging, Advanced Visualization Solutions and Pharmaceutical Diagnostics is translating into segment earnings and offsetting weakness in Patient Care Solutions.
Read each segment’s revenue alongside its Segment EBIT, the company’s measure of segment performance before interest and taxes. Rising revenue with stable or higher Segment EBIT means growth in equipment, diagnostics and services is carrying through rather than being absorbed by costs or product mix; rising revenue with falling Segment EBIT points to pressure on the earnings quality of that growth. Then check whether Patient Care Solutions stabilizes: if it does not, the other segments must carry more of the growth. Together, these figures show whether GE HealthCare’s growth has both scale and earnings support.
Plexus Corp earningsPLXS
Plexus’s report offers a read on whether GE HealthCare is keeping work flowing to this product-development and manufacturing supplier.
First look for any Plexus sales it attributes to GE HealthCare, then compare them with Plexus’s overall sales. Rising GE HealthCare-related sales would indicate more development or manufacturing work from GE HealthCare; falling related sales would show that growth in Plexus’s total sales is not necessarily coming from this customer. If Plexus does not break out those sales, its overall results are only an indirect clue, not proof of GE HealthCare orders.
Fed Interest Rate Decision
The Fed’s policy-rate decision signals the direction of borrowing costs across the economy, which can affect what GE HealthCare pays to refinance or service its debt.
Expected4.0%Last release4.0%
If it comes in above expectations
If the rate is above the estimate, higher borrowing costs could make refinancing maturing debt more expensive and raise interest costs on debt that reprices, leaving less cash for operations and investment.
If it comes in below expectations
If the rate is below the estimate, lower borrowing costs could make refinancing maturing debt cheaper and reduce interest costs on debt that reprices, leaving more cash for operations and investment.
Baxter International Inc. earningsBAX
Baxter’s report will show how hospitals are buying patient-monitoring and cardiac-testing equipment, where its products compete with GE HealthCare’s.
Look for sales or demand signals tied to Baxter’s monitoring and cardiac-testing products, and read them in the context of hospital purchasing. Strength there would indicate that hospitals are still spending on this equipment, in a market where GE HealthCare also competes; weakness could mean slower purchasing or a change in Baxter’s own competitive position. If Baxter does not report these products separately, its overall results cannot by themselves settle demand for GE HealthCare’s monitoring products.
Butterfly Network, Inc. earningsBFLY
Butterfly Network’s report will show whether clinicians are adopting handheld point-of-care ultrasound, where its devices compete with GE HealthCare’s VScan.
Watch sales and growth for Butterfly’s handheld ultrasound, along with its comments on adoption. Faster growth would point to expanding demand for point-of-care ultrasound and potentially greater competition for GE HealthCare’s VScan; slower growth would suggest adoption remains limited, but would not prove that buyers are switching to VScan. The report helps show whether competition in this portable-ultrasound market is intensifying.
iRadimed Corporation earningsIRMD
iRadimed’s report will show whether hospitals are adopting its vital-sign monitor for MRI rooms, a niche where it competes with GE HealthCare.
Watch sales or adoption signals for the 3880 monitor, alongside what iRadimed says about hospitals’ willingness to replace established systems. Rising sales and broader adoption would suggest the newer product is overcoming switching barriers and sharpening competition for GE HealthCare in MRI-room monitoring; slow uptake would suggest established systems still make change difficult and limit that pressure.
KONINKLIJKE PHILIPS N.V. earningsPHG
Philips’s report will show how hospitals and imaging providers are spending on systems, software and services in markets where it competes with GE HealthCare.
Focus on sales and order signals in Philips’s Diagnosis & Treatment business, which combines imaging systems with software around clinical workflow. Stronger demand and orders would show that customers are still investing in imaging and related workflows, in an active market for GE HealthCare too; weakness could point to delayed purchases or a softer market. Philips outperforming or underperforming is a further clue about competitive position, but its overall results alone cannot establish a GE HealthCare gain or loss.
iRhythm Holdings, Inc. earningsIRTC
iRhythm’s report will show demand for its wearable-patch cardiac-monitoring service, which competes with GE HealthCare’s traditional portable ECG recorders.
Watch growth in iRhythm’s long-term ECG monitoring service and any signals about physician orders and patient adoption. Faster growth would indicate stronger demand for its patch-based recording, analysis and reporting, increasing the alternative pressure on GE HealthCare’s traditional ECG recorders; slower growth would suggest the service model is expanding more slowly, but would not prove GE HealthCare’s device sales are rising.
Lantheus Holdings, Inc earningsLNTH
Lantheus’s flurpiridaz royalties offer a read on sales of GE HealthCare’s Flyrcado under their licensing arrangement.
Watch Lantheus’s reported flurpiridaz royalties and any distinction between U.S. and non-U.S. sales, because the royalty terms differ by geography. Rising royalties would indicate more sales of GE HealthCare’s licensed Flyrcado; weaker royalties could mean slower sales growth or a shift in geographic mix. This is an indirect read on Flyrcado, not a measure of GE HealthCare’s entire Pharmaceutical Diagnostics business.
